Skip to main content

Table 1 The clinical characteristics and laboratory findings of 42 patients treated with or without anti-MRSA drugs in this study

From: Clinical impact of methicillin-resistant staphylococcus aureus on bacterial pneumonia: cultivation and 16S ribosomal RNA gene analysis of bronchoalveolar lavage fluid

Clinical variates

Group A

Group B

P-value

Treated with anti-MRSA drugs

Treated without anti-MRSA drugs

(n = 13)

(n = 29)

Age ± SD (years)

74.8 ± 10.1

74.6 ± 17.5

0.764

Male: Female

10:3

19:10

0.458

Underlying diseases**

   

 None

2 (15.4 %)

4 (13.8 %)

0.898

 Malignancies

1 (7.7 %)

11 (37.9 %)

0.016

 Cerebrovascular disorders

5 (38.5 %)

10 (34.5 %)

0.813

 Chronic pulmonary diseases

4 (30.8 %)

5 (17.2 %)

0.382

 COPD

2 (15.4 %)

2 (6.9 %)

0.469

 Bronchiectasis/NTM

1 (7.7 %)

5 (17.2 %)

0.370

 Interstitial lung diseases

1 (7.7 %)

1 (3.4 %)

0.621

 Diabetes mellitus

4 (30.8 %)

3 (10.3 %)

0.178

 Dementia

4 (30.8 %)

6 (20.7 %)

0.519

 Heart diseases

4 (30.8 %)

5 (17.2 %)

0.382

 Hepatic diseases

1 (7.7 %)

1 (3.4 %)

0.621

 Renal diseases

1 (7.7 %)

4 (13.8 %)

0.550

 Hematology/Collagen-vascular diseases

1 (7.7 %)

4 (13.8 %)

0.550

ECOG performance status 3-4

75.0 % (9/12)

60.0 % (15/25)

0.371

Use of Glucocorticoid**/Immunosuppresant

1 (7.7 %)

5 (17.2 %)

0.37

Use of gastric tube

1 (7.7 %)

2 (6.9 %)

0.931

Histories/Risks of aspiration

8 (61.5 %)

15 (51.7 %)

0.568

Antibiotic therapy in the preceding 90 days

5 (38.5 %)

7 (24.1 %)

0.387

History of MRSA detection in the preceding 90 days

4 (30.8 %)

5 (17.2 %)

0.382

Type of pneumonia

   

 CAP

0 (0.0 %)

2 (6.9 %)

0.161

 HCAP

2 (15.4 %)

15 (51.7 %)

0.015

 HAP

11 (84.6 %)

12 (41.3 %)

0.099

Radiologic findings of Chest CT*

   

 Consolidation

7 (63.6 %)

12 (41.4 %)

0.474

 Bronchopneumonia

1 (9.1 %)

9 (31.0 %))

0.052

 Complicated with cavitation/abscess formation

0 (0.0 %)

0 (0.0 %)

 Complicated with atelectasis

0 (0.0 %)

3 (10.3 %)

0.083

 Centrilobular nodules (DPB-like)

0 (0.0 %)

0 (0.0 %)

 Diffuse alveolar shadow (ARDS-like)

2 (18.2 %)

0 (0.0 %)

0.165

 Bronchiectasis

1 (9.1 %)

6 (20.7 %)

0.239

 Parapneumonic pleural effusion

5 (45.5 %)

3 (10.3 %)

0.082

  1. SD standard deviation, COPD chronic obstractive pulmonary disease, NTM nontuberculous mycobacterial infection, MRSA methicillin-resistant Staphylococcus aureus, ECOG Eastern Cooperative Oncology Group, CAP community-acquired pneumonia, HCAP helathcare-associated pneumonia, HAP hospital-acquired pneumonia, CT computed tomography, DPB diffuse pulmonary bronchiolitis, ARDS acute respiratory distress syndrome
  2. *includes diplicates, **corresponds to prednisolone 5 mg daily or greater